维纳卡兰转复近期发作心房颤动的疗效和安全性：系统评价和荟萃分析方案。
Efficacy and safety of vernakalant for cardioversion of recent-onset atrial fibrillation: A protocol for systematic review and meta-analysis.
机构信息
Southwest Medical University, Luzhou, Sichuan, China.
The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, China.
出版信息
Medicine (Baltimore). 2022 Mar 11;101(10):e29038. doi: 10.1097/MD.0000000000029038.
BACKGROUND
Atrial fibrillation (AF) is the most common tachyarrhythmia encountered in clinical practice and is associated with substantial morbidity and mortality. This study aimed to determine the efficacy and safety of vernakalant for cardioversion of recent-onset AF.
METHODS
A comprehensive systematic literature search will be conducted in Cochrane Library, PubMed, Web of Science, EMBASE, for randomized controlled trials (RCTs) about the vernakalant with AF. Two reviewers will independently assess the quality of the selected studies according to the Cochrane Collaboration's tool for RCTs. The bias risk of the RCT will be assessed by the Cochrane risk of bias (ROB) tool. The quality of the evidence will be evaluated by Grading of Recommendations Assessment Development and Evaluation (GRADE) system. Results from these questions will be graphed and assessed using Review Manager 5.3.
RESULTS
The results of this meta-analysis will be published in a peer-reviewed journal.
CONCLUSION
This review will evaluate the safety and efficacy of vernakalant for patients with AF, provide more recommendations for patients or researchers, and high-level evidence for clinical decision-making.
背景
心房颤动（AF）是临床实践中最常见的快速性心律失常，与较高的发病率和死亡率相关。本研究旨在确定维纳卡兰在治疗新发 AF 中的疗效和安全性。
方法
我们将对 Cochrane 图书馆、PubMed、Web of Science、EMBASE 中的关于维纳卡兰治疗 AF 的随机对照试验（RCT）进行全面的系统文献检索。两名评审员将根据 Cochrane 协作网的 RCT 工具独立评估所选研究的质量。RCT 的偏倚风险将通过 Cochrane 偏倚风险（ROB）工具进行评估。证据质量将通过推荐评估、制定与评价分级（GRADE）系统进行评估。这些问题的结果将使用 Review Manager 5.3 进行图表绘制和评估。
结果
这项荟萃分析的结果将发表在同行评议的期刊上。
结论
本综述将评估维纳卡兰治疗 AF 患者的安全性和疗效，为患者或研究人员提供更多建议，并为临床决策提供更高水平的证据。
Zotero 插件